Trials / Completed
CompletedNCT05963282
Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 9,870 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a non-interventional retrospective cohort study of de novo heart failure with reduced ejection fraction (HFrEF) patients (aged ≥18 years) commencing first-line treatment on either sacubitril/valsartan or commencing or continuing angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blocker (ARB) therapy for HF in the United States (US) using the secondary source of data, Optum Electronic Health Records (EHR).
Conditions
Timeline
- Start date
- 2021-11-29
- Primary completion
- 2022-07-19
- Completion
- 2022-07-19
- First posted
- 2023-07-27
- Last updated
- 2023-07-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05963282. Inclusion in this directory is not an endorsement.